GMAB Stock Price, Chart, Stats & News
GMAB chart
Fundamentals
Gross margin | 93.19% |
Operating margin | 31.23% |
Pretax margin | 26.23% |
Net margin | 20.40% |
Effective tax rate | 22.20% |
ROA | 3.57% |
ROE | 10.61% |
D/E | 0.95x |
Interest coverage ratio | 12.98x |
GMAB valuation
P/E | 18.23x |
P/S | 7.21x |
P/B | 2.78x |
P/CF | 21.54x |
P/FCF | 23.25x |
P/OCF | 21.54x |
PEG | -0.10x |
EV multiple | 15.30x |
About
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies.
Similar securities
Based on sector and market capitalization
